Glaucoma procedure now available at Mayo Clinic aims to prevent further eye damageJune 26, 2008JACKSONVILLE - For the first time in Florida, patients with glaucoma have a new treatment option known as the Trabectome. The minimally invasive procedure, which is available at Mayo Clinic and takes about 20 minutes, is designed to decrease pressure within the eye and stabilize the vision. "The goal of this procedure is to prevent further damage within the eye," says ophthalmologist Rajesh Shetty, M.D. He says that some patients have been able to reduce or eliminate use of daily eye drop medications that regulate intraocular pressure. Glaucoma, the second leading cause of blindness, is a disease that causes irreversible damage to the optic nerve from increasing pressure within the eye. This occurs because the eye produces a clear fluid that does not drain adequately and raises the eye pressure. The first sign of glaucoma is a loss of peripheral vision that is usually not noticed by the patient until it affects the central vision. Unfortunately, vision lost to glaucoma can't be restored so treatment aims to reduce eye pressure to prevent further damage.
Traditionally, ophthalmologists first prescribe eye drops to reduce the eye pressure, and if that doesn't work, they can perform a laser procedure (trabeculoplasty) to the existing internal drainage canal around the base of the cornea. A more invasive treatment is trabeculectomy, a surgical technique to create a new drain for the eye. The Trabectome procedure uses a small probe that opens the eye's drainage system through a tiny incision in the eye's cornea. "It removes a small portion of the eye's natural drainage system so that it functions better," says Dr. Shetty. He says it should be used when eye drops and laser trabeculoplasty fail to reduce pressure and before trabeculectomy is considered. "I see this as another rung in the ladder of treatment for glaucoma," he says. So far, more than a dozen patients have had the procedure at Mayo Clinic in Florida, although the technique has been available at Mayo Clinic in Rochester for a few years. To date, several thousand procedures have been done nationwide, according to Dr. Shetty. The procedure requires very little sedation and patients generally recover within a week. "We have been pleased with the results," he says, noting that although lost vision cannot be restored with the procedure, some patients have reported improved vision overall after surgery. An estimated 4 million Americans are affected by glaucoma. Glaucoma screenings are suggested for anyone over 40 every two to four years. A routine exam can help identify risk for glaucoma and early signs of the disease. Risk factors for glaucoma include: a family history of the disease, African or Hispanic ancestry, diabetes, certain rare eye diseases and having had an eye injury or having used any corticosteroid preparation for a prolonged period. Mayo Clinic | |||||||||||||||||||||
|
Related Glaucoma Current Events and Glaucoma News Articles Melatonin may save eyesight in inflammatory disease Current research suggests that melatonin therapy may help treat uveitis, a common inflammatory eye disease. The related report by Sande et al., "Therapeutic Effect of Melatonin in Experimental Uveitis," appears in the December issue of The American Journal of Pathology. Eye conditions linked with obstructive sleep apnea If a good night's sleep helps the brain and body perform better, it's a good guess that sleep problems can cause more than just fatigue. Numerous studies have shown a connection between sleep disorders and medical conditions such as cardiovascular disease, cerebrovascular disease, and metabolic disorders, including the risk of obesity and diabetes mellitus. In the November issue of Mayo Clinic Proceedings, Mayo Clinic researchers outline several interesting associations between sleep disorders and eye disease. Vision loss more common in people with diabetes Visual impairment appears to be more common in people with diabetes than in those without the disease, according to a report in the October issue of Archives of Ophthalmology, one of the JAMA/Archives journals. Medication slows progression of myopia in children Daily treatment with a medication called pirenzepine can slow the rate of progressive myopia, or nearsightedness, in children, reports a study in the August issue of the Journal of AAPOS (American Association for Pediatric Ophthalmology and Strabismus). Case Western Reserve and Penn State investigators inhibit corneal inflammation Researchers from the Case Western Reserve University School of Medicine and Penn State Hershey College of Medicine identified a novel therapeutic that reduces sterile inflammation within the cornea. Glaucoma report points to increased costs A new Centre for Eye Research Australia/ Access Economics report shows the cost of glaucoma will more than double in the next two decades. 'Fluorescent' cells give early warning for eye disease Scientists at the University of Michigan have shown that their new metabolic imaging instrument can accurately detect eye disease at a very early stage. Role identified for glaucoma gene and related signaling pathway Researchers have found that a gene and a related signaling pathway play a role in the development of glaucoma, which is a common cause of visual impairment and blindness worldwide. Cost of glaucoma medications may impact treatment In the United States, the management of glaucoma costs about $2.5 billion per year. Of the $1.9 billion in direct costs, glaucoma medications account for an estimated 38% to 52% of the total. Using fMRI to study brain development Functional magnetic resonance imaging (fMRI) is a powerful noninvasive tool for studying brain activity in both humans and experimental animals. More Glaucoma Current Events and Glaucoma News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||